OCT 0 1 2002 3

ADMPTHE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 1 0 2002

TECH CENTER 1600/2900

In re

Application of:

Stuart A. Newman, et al.

Serial No.:

09/849,967

Examiner: Natalie Davis

Filed:

May 8, 2001

Group: 1642

For:

SPLICE CHOICE ANTAGONISTS AS THERAPEUTIC AGENTS

Attorney Docket #:

51230-00601

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated September 4, 2002, please consider the following remarks regarding the above-referenced patent application.

REMARKS

Claims 1-54 are pending in the application. Applicant respectfully requests reconsideration of the restriction in view of the following remarks.

I. RESTRICTION TO GROUPS I, II, III, IV, V AND VI.

The Invention of Groups I-V (methods) and VI (products) are related as products and processes of use. In compliance with the restriction, Applicant elects to prosecute Group I, claims 1-22 and 37-42, with traverse. Groups II-VI claims 23-36 and 43-54 are withdrawn from further consideration. Applicant respectfully requests the withdrawal of the restriction requirement and the examination of restricted claims upon consideration of the remarks below or upon the allowance of a generic and/or linking claim in Group I. Applicant reserves the right to file a divisional application directed to any non-elected claims.

Doc. 651277/Version 2